Yossi Mazel, Bendit Technologies - Steerable Microcatheter | LSI Europe '22

Transcription

Yossi Mazel  0:04  

Hi, I'm Yossi Mazel, CEO of Bendit Technologies from Israel. I love to present to such an intimate audience and I think maybe each one of you can present himself and we can do first name basis. So Bendit is a growth stage company with initial US sales for an FDA cleared microcatheter a steerable catheter indicated for Neuro coronary, and embracing a capital of a $10 million, as I mentioned, Israeli company founded to 13. So we've been here a while. In 219, we cleared the device C and the FDA just for the peripheral indication. And in a previous round, we had Varian medical systems, which is part of Siemens and Indico and tech vault from Italy as our investors. Now they say a picture's worth 1000 words. So this video is worth millions. So for those of you understand catheters, you have a slider that is able to deflect the tip of the catheter and this is unique. Complete control deflection allows you for better navigation, you have a micro Torker so you can control the tip of the catheter or you can rotate the handle for a full rotation of the catheter. Even if you challenge it, it still operates functions perfectly. So even like I said, even if goes through torturous anatomy, you still have control of sort of deflection, you can still navigate as little as you want into the brain. Now typically, catheters are used with guide wires and here you see an 18 guide wire coming out of the bandit, but the novelty of the technology is that it can be used without guide wires saving a lot of time and equipment. So basically, the catheter can go all the way from growing to brain without the use of guide wires. Second novelty here you see the bendit coming out of a five French aspiration catheter aspiration catheter is used to aspirate blood clots from the brain and the bend that is strong enough to deflect this aspiration catheter and point it all the way to the character ID. Now when physicians see this, they see three things First, they say wow, second, they said we have patients I have patients that could benefit from this right now. And the third thing they say we want to invest Okay, so this is this is quite unique. Basically this pair bedded catheter and aspiration catheter can go all the way from groin to the brain. And you're gonna see the bendits inside the silicone model. You can see aspiration, catheter tracking very, very nicely. You can see the bandit able to enter an aneurysm this is when you supposed to say wow, wow, impressive. Come on. Okay, the team. The team, headed by Chairman Rich Cappetta was a veteran of this industry used to be the president and CEO of microvention Os Kabiri is a successful Israeli entrepreneur. Dr. Alex Bernstein from Mount Sinai is one of the pioneering of this indication no hero intervention, as I mentioned over 25 neuro interventional is direct investors in the company to the sum of a few million dollars, myself over 20 years experience in the medical Israeli medical devices industry. So today, when neuro interventional is use catheters, they need to first use a guide wire and on top of the guide wire, they have to put the catheter and these results in poor access to in torturous anatomy. In exchanges that are time consuming, you have to put a guide wire or take out the guide wire, put a new guide wire, there is poor control of the control site or where you want to do the treatment, it requires a lot of training of what we say good hands, a good pair of hands, okay. And obviously, there are additional costs for the of the guide wires, what the catheter you just saw gives is perfect control. Even in complex obviously in simple anatomies you have complete control of the tip as an operator, it is very intuitive to use, you don't need secondary equipment. And if I go straight down to actual usage, when I look at the neuro indication, the first thing that we've we've shown already is less time to treat stroke. Okay, and this is huge, I mean stroke. You all know the expression time is brain Okay, the ability to treat stroke in less time is huge implications. Okay. The second important indication in neuro is the ability to deliver intracellular device precisely and accurately into aneurysm to treat them. In terms of the peripheral indication, which is the secondary indication the most interesting one is what's called on interventional oncology, the ability to treat liver cancer and deliver chemotherapy beads or radiotherapy beads directly or tumors and you can deliver to specific locations in the liver without having to use guide wires again saving a lot of time and procedure time. In terms of the size of the market, it's a very, very significant market, around a billion dollar market, 40% of it is in the US. It's growing very, very significantly as their becomes their as more awareness to stroke procedures a aneurysm procedure. So this market is growing significantly. There is also a big growth in the Far East, especially in China and in the for this indication in terms of the what we call this time, a secondary market which is the peripheral market also huge growth of this market specifically, I mean, this is a multidisciplinary a indication Okay, the peripheral education, we're at this time looking more closely at the interventional ecology and also this market is going very, very fastly. In terms of what we're doing right now, were soft launching or controlled launching it in the US. We have orders from multiple US hospitals. This week as we speak, we've launched a two additional hospitals. So that's our second and third hospital. We're going to run soon our four so we're doing a very controlled we want to do a commercial proof of concept in 10 US hospitals and a so we started in July at Mount Sinai Hospital in New York. We already have a second order from this hospital and this week, we have a lucky team from Ben Deaton Honolulu doing cases a at Queen's Hospital we have another team in New York doing a Stony Brook New York doing cases with Dr. Fiorella. So like I said, We want good results. This is the purpose of the soft launch is to is to a demonstrate the commercial traction of the device or recurring revenue justifying the price of the device. In terms of pipeline we have a second device coming so the first device that is FDA cleared is an O.1 device which means on 0.1 a of an inch as an inter the inner diameter we have a second device a 17 Close to design freeze that we hope to submit to the FDA sometime in the next year. Apart from that based on the IP we can do a additional devices for specific indication like I said coronary peripheral neuro and also a different types of guide wires. In terms of of what we're planning to do in the next couple of years, transfer the production from Israel to the US continue with the r&d and commercial a continue to commercial commercialization just in the US. For this I'm raising up to $10 million in a seed round. A basically I'm looking for a lead investor and the rest of my current investable, probably a joint this investment questions. So I'm here on a Saturday, feel free to reach out email me or call me. Thank you for your time and attention.